H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of $40.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising potential of Syndax Pharmaceuticals’ Revuforj in treating acute myeloid leukemia (AML). The recent data presented at ASH 2025 demonstrated that Revuforj’s strong trial responses are effectively translating into real-world settings, even among patients with advanced disease and complex treatment histories. This rapid time to response and consistent efficacy across various treatment settings underscore the drug’s potential as a backbone therapy in AML treatment.
Furthermore, the increasing adoption of Revuforj, especially after its approval for relapsed or refractory NPM1 mutated AML, indicates a growing demand and broader use in clinical practice. The data also showed high minimal residual disease (MRD) negativity rates in frontline intensive chemotherapy combinations, reinforcing confidence in the drug’s pivotal programs. The manageable safety profile and compatibility with supportive care medications further reduce commercial barriers, supporting the belief that Revuforj will achieve significant market success.
According to TipRanks, Y. Maldonado is a 5-star analyst with an average return of 16.2% and a 54.19% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, Candel Therapeutics, and Syndax Pharmaceuticals.
In another report released today, Barclays also maintained a Buy rating on the stock with a $35.00 price target.